Emmanuelle Charpentier co-founded CRISPR Therapeutics in 2013 alongside Rodger Novak and Shaun Foy. The company focuses on developing the CRISPR-Cas genome engineering technology for applications in biotechnology and biomedicine. This groundbreaking approach has positioned CRISPR Therapeutics at the forefront of gene-editing therapies.
EN